Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

Doxazosin and finasteride negatively affect sexual function in men with BPH.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This review discusses the management options for recurrent ischemic priapism, noting that ketoconazole, finasteride, and other hormonal therapies may be effective but can have significant side effects; it reports no new clinical findings.

This study found that the 1 mg dose of finasteride was associated with a wide range of adverse effects, including sexual, psychological, and metabolic symptoms, in the FAERS data.

In this study, oral finasteride treatment for four weeks reduced the weight of the corpus cavernosum in rats but did not significantly affect erectile function.

This review focuses on recent advancements in understanding and treating ischemic and nonischemic priapism, but does not present new clinical results.

This review summarizes key characteristics of men's health issues such as erectile dysfunction and prostate cancer, along with specific nursing considerations, and reports no new research results.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.

This review discusses the potential persistent adverse effects associated with 5α reductase inhibitor treatment for androgenetic alopecia but provides no new clinical results; it emphasizes the importance of discussing these risks with patients.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study concluded that administering dutasteride for more than 8 weeks in rats could lead to irreversible erectile dysfunction, even after stopping the medication.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This review discusses methods for improving study design and evaluation in sexual health literature and reports no new clinical results; it highlights current methodological issues and the benefits of validated questionnaires.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.

This review discusses the prevalence and etiologies of sexual dysfunction in young men, highlighting the increased recognition of organic causes alongside psychosomatic factors, and reports no new clinical results.

This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.

This review synthesizes evidence on the prevalence, impacts, causes, and treatment of erectile dysfunction in men under 40 but reports no new clinical results; the authors emphasize the need for comprehensive evaluation and individualized care.

This review explores how technologies like telemedicine, wearable devices, bioengineering, and digital therapeutics are enhancing the management of sexual dysfunction in patients with chronic diseases by offering personalized and accessible solutions, although traditional approaches often fall short.

In this animal study, finasteride treatment altered testosterone metabolism in rat corpus cavernosum, linked to mechanisms of erectile dysfunction, but these changes were reversed after stopping the drug, suggesting post-treatment sexual side effects may relate more to central control dysfunction than peripheral issues.

The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.

This review discusses the use of platelet-rich plasma injections for treating erectile dysfunction, noting the potential for regenerative medicine to reverse or halt disease progression, but it reports no new clinical results.